Evidence map›Paper›PMID 35890372›Full record

ArticlePharmaceutics2022

The Ca

José Ignacio Veytia-Bucheli, Den Alejandro Alvarado-Velázquez, Lourival Domingos Possani, Roberto González-Amaro, Yvonne Rosenstein

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

José Ignacio Veytia-BucheliDepartamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Av. Universidad 2001, Cuernavaca 62210, Mexico.ORCID 0000-0003-4165-2884
Den Alejandro Alvarado-VelázquezDepartamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Av. Universidad 2001, Cuernavaca 62210, Mexico.ORCID 0000-0002-6135-4158
Lourival Domingos PossaniDepartamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Av. Universidad 2001, Cuernavaca 62210, Mexico.ORCID 0000-0001-6357-2661
Roberto González-AmaroCentro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona 550, San Luis Potosí 78210, Mexico.ORCID 0000-0001-6025-7375
Yvonne RosensteinDepartamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Av. Universidad 2001, Cuernavaca 62210, Mexico.ORCID 0000-0003-4040-4256
Universidad Nacional Autónoma de México · MXAutonomous University of San Luis Potosí · MXUniversidad Autónoma del Estado de Morelos · MXUniversity of Namur · BE

Funding

Consejo Nacional de Ciencia y Tecnología A1-S-15601National Autonomous University of Mexico IN212519
6 · The paper itself

Abstract

Ca

Indexed as

Ca2+ channel blockerscytokine productionimmunosuppressionT cell activationverapamil

Identifiers

PMID35890372
PMCPMC9324055
OpenAlexW4285733617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.